Diagnosed with Non-Small Cell Lung Cancer (NSCLC) and Immunotherapy not Working?
Researchers at the National Cancer Institute, National Institutes of Health are evaluating a new combination of investigational therapies to treat non-small cell lung cancer (NSCLC) in the future. Click below to join our study.
Conducted Nationwide
Previous Frontline Therapy
18+ Years Old
Travel & Lodging Provided
Diagnosed with Non-Small Cell Lung Cancer
Fast Facts
Not A Surgical Candidate
Study Background Our researchers want to determine whether combining inhaled antibiotics and an immune checkpoint inhibitor can help non-small cell lung cancer patients who cannot have surgery. These combined investigational treatments may help your immune system's T cells kill cancer cells. If immunotherapy has stopped working for you, you may qualify to participate in our research study. Your participation in this study may help researchers develop treatments for advanced non-small cell lung cancer patients. Join our research study today. PI: Chen Zhao |
Additional Information
Our goal is to determine whether combining inhaled antibiotics and an immune checkpoint inhibitor can help non-small cell lung cancer patients not amenable to surgery.
You may qualify to participate in this study if you meet the following criteria.
Key Criteria:
Key Criteria:
- 18+ years old
- Diagnosed with non-small cell lung cancer that is not amenable to surgery
- Previously received at least one line of standard frontline treatment
- Not pregnant or breastfeeding
- No other major autoimmune or medical conditions
Once you enroll in the study, participation involves 6 cycles of treatments. Each cycle is 3 weeks (21 days).
- On day 1 of each cycle, you receive pembrolizumab.
- During cycles 1, 3, and 5, participants will self-administer aerosolized (inhaled) aztreonam 3 times a day and vancomycin 2 times a day from days 2-21.
There is no cost for you to participate in our research program. Travel and lodging will be provided.